OS Therapies Inc Logo

OS Therapies Inc

Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.

OSTX | US

Overview

Corporate Details

ISIN(s):
US68764Y2072
LEI:
Country:
United States of America
Address:
15825 SHADY GROVE ROAD, 20850 ROCKVILLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

OS Therapies Inc. is a clinical-stage immunotherapy company focused on the development and commercialization of treatments for cancer. The company develops therapies designed to activate the patient's immune system to target and kill cancers expressing the HER2 protein. Its lead candidate, OST-HER2, is a cancer vaccine primarily targeting Osteosarcoma, a type of bone cancer with a significant unmet medical need in both pediatric and adult patients. OS Therapies is also planning to expand its therapeutic development into other HER2-expressing solid tumors, including breast, colorectal, esophageal, lung, and ovarian cancers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all OS Therapies Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OS Therapies Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OS Therapies Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Matinas BioPharma Holdings, Inc. Logo
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
United States of America
MTNB
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel
MTLF

Talk to a Data Expert

Have a question? We'll get back to you promptly.